Rhythm Pharmaceuticals develops and sells IMCIVREE, a treatment for rare genetic forms of obesity. It last closed at $112.36 on Nov 20, down 3.80% on the day. The next earnings report for RYTM is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, RYTM reported EPS of -$0.61 on revenue of $92.1M, with revenue up 79.6% from a year ago. Over its last 8 reports the stock moved an average of 4.5% the session after earnings. Over the last 12 months RYTM insiders bought $0 of stock on the open market and sold $43.0M, according to SEC Form 4 filings.
AI Auto Pilots
Is RYTM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RYTM.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on RYTMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
RYTM · as of the Nov 20 close · updated each morning
Uptrend
The stock is 6% above its 20 day and 13% above its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the swing low (Aug 12) at $111.42, and the nearest resistance the Pivot at $113.79.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 5.4%/day
Key levels
$122.2052 week high+8.8%
$115.58Pivot R1+2.9%
$114.75Swing high (Aug 26)+2.1%
$113.79Pivot+1.3%
$112.36Last close
$111.42Swing low (Aug 12)−0.8%
$110.57Pivot S1−1.6%
$105.2220 day average−6.4%
$103.48100 day average−7.9%
$98.0850 day average−12.7%
$97.45200 day average−13.3%
$74.5052 week low−33.7%
Indicators
RSI (14)
57.21
Middle of its range
Neutral
MACD
5.71
Above its signal line
Bullish
Stochastic
86.6
Near the top of its range
Overbought
ADX (14)
30.7
Trending up
Williams %R
-22.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
62.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+0.1%
Change over 10 sessions
Bullish
ATR (14)
$6.03
Typical daily range, 5.4% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 9.5%/day
Key levels
$122.2052 week high+8.8%
$115.58Pivot R1+2.9%
$114.75Swing high (Aug 26)+2.1%
$113.79Pivot+1.3%
$112.36Last close
$111.42Swing low (Aug 12)−0.8%
$110.57Pivot S1−1.6%
$105.2220 day average−6.4%
$103.48100 day average−7.9%
$98.0850 day average−12.7%
$97.45200 day average−13.3%
$74.5052 week low−33.7%
Indicators
RSI (14)
59.04
Middle of its range
Neutral
MACD
1.98
Above its signal line
Bullish
Stochastic
81.8
Near the top of its range
Overbought
ADX (14)
17.8
No clear trend
Williams %R
-22.7
Oversold below −80, overbought above −20
Neutral
CCI (20)
93.2
Oversold below −100, overbought above 100
Neutral
Rate of change
+7.3%
Change over 10 sessions
Bullish
ATR (14)
$10.70
Typical daily range, 9.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for RYTM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RYTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow RYTM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for RYTMHow many large options trades hit RYTM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in RYTM in the last 90 days.
From SEC Form 4 filings by RYTM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RYTM is in one of them and how their past RYTM trades turned out.
Rhythm Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, in the United States. It sells IMCIVREE, a treatment that acts on the MC4R pathway in the brain, for patients with certain rare genetic forms of obesity, such as Bardet Biedl syndrome. The company is also developing other MC4R agonist treatments for hypothalamic obesity and other rare conditions. Its customers are patients with these rare diseases, along with the physicians and healthcare providers who treat them.